Ownership Capital B.V. Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Ownership Capital B.V. trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 7.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 701,971 shares of the medical device company's stock after selling 59,839 shares during the quarter. DexCom accounts for 2.0% of Ownership Capital B.V.'s portfolio, making the stock its 20th largest holding. Ownership Capital B.V. owned approximately 0.18% of DexCom worth $54,592,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ieq Capital LLC increased its stake in shares of DexCom by 149.9% in the fourth quarter. Ieq Capital LLC now owns 52,744 shares of the medical device company's stock valued at $4,102,000 after buying an additional 31,641 shares in the last quarter. Private Advisor Group LLC increased its position in DexCom by 33.8% in the fourth quarter. Private Advisor Group LLC now owns 15,149 shares of the medical device company's stock worth $1,178,000 after purchasing an additional 3,831 shares during the period. Alberta Investment Management Corp increased its position in DexCom by 13.7% in the fourth quarter. Alberta Investment Management Corp now owns 302,357 shares of the medical device company's stock worth $23,514,000 after purchasing an additional 36,500 shares during the period. Cardinal Capital Management bought a new position in DexCom during the fourth quarter worth about $3,459,000. Finally, Kornitzer Capital Management Inc. KS lifted its holdings in shares of DexCom by 45.5% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 55,752 shares of the medical device company's stock valued at $4,336,000 after purchasing an additional 17,435 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. JPMorgan Chase & Co. boosted their target price on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Leerink Partners decreased their target price on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Wells Fargo & Company upped their price objective on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th. Citigroup upped their price objective on DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group upped their target price on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $99.06.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by insiders.

DexCom Stock Down 0.6 %

NASDAQ:DXCM traded down $0.56 during mid-day trading on Friday, reaching $88.78. The company's stock had a trading volume of 3,729,437 shares, compared to its average volume of 3,632,823. The firm has a market capitalization of $34.69 billion, a PE ratio of 62.08, a price-to-earnings-growth ratio of 2.31 and a beta of 1.14. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a fifty day moving average of $83.26 and a 200-day moving average of $75.94. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.